HAIN PANEL: 1ST&2ND LINE DRUG SUSCEPTIBILITY (LPA)
Report turn around time
after 7 days
HAIN is the Line probe assay, DNA-based molecular test. The novel diagnostic test - called MTBDRplus is a multiplex PCR based on DNA-strip technology that identifies genetic mutations in TB strains, making them resistant to isoniazid and rifampicin. It is the first rapid genetic assay approved by WHO used for anti-Mycobacterial drugs susceptibility test. MTBDRplus (HAIN first line) is used to detect Mycobacterium tuberculosis complex directly and isoniazid and rifampicin susceptibility to it, which is very helpful to diagnose MDR tuberculosis in a very short period of time. Resistance to rifampicin is a critical pre-requisite for identifying patients who can be put on second line anti-TB regimen. It is fully automated amplification and detection technique allowing reliable nucleic acid extraction from different sample materials. It is suitable and economical for low, mid and high throughput, one single platform for direct detection, drug susceptibility testing and differentiation. According to WHO recommendations it is used for the direct testing of sputum specimens as well as indirect testing on culture isolates from rifampicin-resistant or MDR-TB patients, including adults and children (irrespective of the smear status). It does not eliminate the need for phenotypic DST to confirm resistance to other drugs and to monitor the emergence of additional drug resistance during treatment.